Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eftilagimod alpha - Immutep Limited

Drug Profile

Eftilagimod alpha - Immutep Limited

Alternative Names: EDP 202; Efti; EOC-202; hLAG-3Ig; ImmuFact IMP321; ImmuFact-IMP321; IMP 321; LAG-3-Ig-fusion-protein; LAG-3Ig; sLAG-3-Ig

Latest Information Update: 07 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immutep
  • Developer CYTLIMIC; EOC Pharma; Immutep; Immutep Limited; Krankenhaus Nordwest; Merck & Co; Prima BioMed
  • Class Adjuvants; Antineoplastics; CD antigens; Immunoglobulins; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Histocompatibility antigen class II stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Breast cancer
  • Phase II COVID 2019 infections; Non-small cell lung cancer; Soft tissue sarcoma; Squamous cell cancer
  • Phase I Liver cancer; Malignant melanoma; Solid tumours
  • No development reported Renal cell carcinoma
  • Discontinued Hepatitis B

Most Recent Events

  • 05 Mar 2024 Efficacy and adverse events data from the phase II/III AIPAC-003 trial in Breast cancer released by Immutep Limited
  • 21 Dec 2023 Paul-Ehrlich-Institut (PEI) provides positive feedback for eftilagimod alpha for TACTI 004 phase-III trial for Non-small cell lung cancer (First-line therapy, Metastatic disease)
  • 09 Nov 2023 Immutep and Merck Sharp & Dohme completes enrollment in the phase II TACTI-003 trial for Squamous cell carcinoma of head and neck (First line therapy, Metastatic disease, Combination therapy, Inoperable/Unresectable) in the US, Australia, Belgium, Denmark, Germany, Spain, Romania, Ukraine, and the UK (SC) (NCT04811027)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top